Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta-Analysis Approach.
Body Mass Index
Contraceptive Agents, Hormonal
/ administration & dosage
Contraceptives, Oral, Combined
/ administration & dosage
Contraceptives, Oral, Synthetic
/ administration & dosage
Cytochrome P-450 CYP3A Inducers
/ adverse effects
Dose-Response Relationship, Drug
Drug Combinations
Drug Interactions
Ethinyl Estradiol
/ administration & dosage
Female
Humans
Levonorgestrel
/ administration & dosage
Models, Biological
Obesity
/ physiopathology
Pregnancy
Pregnancy, Unplanned
Risk Assessment
Risk Factors
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
28
06
2021
accepted:
07
10
2021
pubmed:
22
10
2021
medline:
22
2
2022
entrez:
21
10
2021
Statut:
ppublish
Résumé
Combined oral contraceptive pills are the most commonly used hormonal contraceptives for the prevention of unintended pregnancies in United States. They consist of a progestin (e.g., levonorgestrel (LNG)) and an estrogen component, typically ethinyl estradiol (EE). In addition to adherence issues, drug-drug interactions (DDIs) and obesity (women with body mass index (BMI) ≥ 30 kg/m
Substances chimiques
Contraceptive Agents, Hormonal
0
Contraceptives, Oral, Combined
0
Contraceptives, Oral, Synthetic
0
Cytochrome P-450 CYP3A Inducers
0
Drug Combinations
0
ethinyl estradiol, levonorgestrel drug combination
0
Ethinyl Estradiol
423D2T571U
Levonorgestrel
5W7SIA7YZW
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-518Subventions
Organisme : Bill & Melinda Gates Foundation
ID : OPP1185454
Pays : United States
Informations de copyright
© 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics.
Références
Nations, U. Department of Economic and Social Affairs, Population Division (2019). Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435).
Daniels, K. & Jones, K. Current Contraceptive Status Among Women Aged 15-44: United States, 2011-2013. NCHS data brief, no. 173 (National Center for Health Statistics, Hyattsville, MD, 2014)
Daniels, K. & Abma, J.C. Current Contraceptive Status Among Women Aged 15-49: United States, 2015-2017. NCHS Data Brief, no. 327 (National Center for Health Statistics, Hyattsville, MD, 2018).
Akbar, M. et al. FDA public meeting report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”. J. Clin. Pharmacol. 58, 1655-1665 (2018).
Lesko, L.J. et al. Establishing a multidisciplinary framework to study drug-drug interactions of hormonal contraceptives: an invitation to collaborate. CPT Pharmacometrics Syst. Pharmacol. 7, 706-708 (2018).
Winner, B. et al. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 366, 1998-2007 (2012).
Trussell, J. & Portman, D. The creeping Pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception 88, 604-610 (2013).
Sharifi, H., Hasanloei, M.A. & Mahmoudi, J. Polypharmacy-induced drug-drug interactions; threats to patient safety. Drug Res. (Stuttg). 64, 633-637 (2014).
Center For Drug Evaluation and Research, Food and Drug Administration. Labeling for Combined Hormonal Contraceptives: Guidance for Industry (Draft Guidance) (Center For Drug Evaluation and Research, US Food and Drug Administration, Bethesda, MD, 2017).
Zhang, N. et al. Role of CYP3A in oral contraceptives clearance. Clin. Transl. Sci. 11, 251-260 (2018).
Cicali, B. et al. Quantitative assessment of levonorgestrel enzyme-binding partner interplay and drug-drug interactions using physiologically based pharmacokinetic modeling. CPT Pharmacometrics Syst. Pharmacol. 10, 48-58 (2021).
Kuhl, H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8(Suppl 1), 3-63 (2005).
Mould, D. Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin. Pharmacol. Ther. 92, 283-286 (2012).
Electronic medicines compendium, Norgestron SmPC <https://www.medicines.org.uk/emc/medicine/1834>.
Schindler, A.E. et al. Classification and pharmacology of progestins. Maturitas 46(Suppl 1), S7-S16 (2003).
Bastianelli, C., Farris, M., Rosato, E., Brosens, I. & Benagiano, G. Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation. Expert Rev. Clin. Pharmacol. 11, 1085-1098 (2018).
Sunaga, T., Cicali, B., Schmidt, S. & Brown, J. Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system. Contraception 103, 222-224 (2021).
Cherala, G., Edelman, A., Dorflinger, L. & Stanczyk, F.Z. The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy. Contraception 94, 104-108 (2016).
Benagiano, G. & Primiero, F.M. Long acting contraceptives. Present status. Drugs 25, 570-609 (1983).
Croxatto, H.B. NORPLANT: levonorgestrel-releasing contraceptive implant. Ann. Med. 25, 155-160 (1993).
Perry, S.H. et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS 28, 791-793 (2014).
Lopez, L.M. et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 8, CD008452 (2016).
Yamazaki, M. et al. Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis. Contraception 92, 445-452 (2015).
Phillips, A., Demarest, K., Hahn, D.W., Wong, F. & McGuire, J.L. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 41, 399-410 (1990).
Li, Q.G. & Hümpel, M. Serum protein binding characteristics of cyproterone acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man. J. Steroid Biochem. 35, 319-326 (1990).
Kuhnz, W., Staks, T. & Jütting, G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Contraception 50, 563-579 (1994).